NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Sativa Wellness Group Inc.
("Sativa" or "Sativa Wellness" the "Company" or the "Group")
7 January 2021
December Record Sales
We are pleased to advise that December 2020 was another record sales month for Sativa Wellness Group.
2020 was a transformational year for the company as we combined with Stillcanna Inc. to create a leading European seed to consumer company in the CBD wellness market. Having a fully integrated supply chain allows us to control both quality and costs. Producing a traceable high-quality product has never been more important than today as we approach the UK FSA Novel Food validation deadline at the end of March. Sativa is well prepared for this process and embraces a market with high quality, compliant products.
In 2021 our sights are on continuing to drive sales in the UK and truly extending our reach into Europe. We already have a strong presence in Europe with our extraction and production plant, and we are now extending our capabilities to sell and distribute our products in European markets.
All the best for a safe, healthy, happy and prosperous 2021.
The Directors of the Company accept responsibility for the contents of this announcement.
On behalf of the Board of Directors,
This information is provided by RNS, the news service of the
. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom
. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org
or visit www.rns.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the